Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets

Christopher J. Magnani[1], Vincent D. D'Andrea[1,2], Guilherme Garcia Barros[3], Zhiyu Qian[1], John Ernandez[1], Kendrick Yim[1], Adam S. Kibel[1], Steven L. Chang[1], Matthew Mossanen[1], Mark A. Preston[1], Adam S. Feldman[4], Bernard H. Bochner[2], David B. Solit[5,6], Eugene J. Pietzak[2], Kent W. Mouw[7], Filipe L.F. Carvalho[1,†], Timothy N. Clinton[1,†]

[†] These authors contributed equally as co-corresponding authors.

1. Department of Urology, Brigham and Women's Hospital, Boston, MA
2. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
3. Department of Urology, University of São Paulo, São Paulo, Brazil
4. Massachusetts General Hospital, Harvard Medical School, Boston, MA
5. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
6. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
7. Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA

Corresponding author:

Filipe L.F. Carvalho
45 Francis St, ASB2-3
Boston, MA
Phone: 508-718-4519
fcarvalho@bwh.harvard.edu

ABSTRACT:

Purpose: Younger patients with bladder cancer typically have fewer environmental exposures or risk factors, suggesting that the molecular pathways implicated in early-onset disease differ from those in older patients. Dissecting the genomic profiles of early-onset tumors may inform targeted treatment strategies for young patients. We compared the frequency of somatic mutations in early-onset bladder cancer, defined as a diagnosis before the age of 55 years, which encompasses the youngest patients in about 1 in 10 diagnoses based on national registries.

Material and methods: We assessed two institutional cohorts: the Mass General Brigham Young Cystectomy Cohort (MGB-YCC, n=134 patients) from 2008-2023 and the Memorial Sloan-Kettering-IMPACT bladder cancer cohort (MSK-IMPACT, n=1271) from 2014-2021. Clinical outcomes of MGB-YCC were also compared with published data from patients undergoing cystectomy in the National Surgical Quality Improvement Program (NSQIP, n=10,848) from 2008-2013.

Results: Both the MGB-YCC and MSK-IMPACT cohorts were predominantly male (>76%), and younger patients were less likely to have a history of smoking or muscle-invasive disease. MGB-YCC demonstrated more patients with continent diversions (51.5% vs 14.9%) than the older population in NSQIP, although complication rates were similar. Genomic characterization of MGB-YCC demonstrated *KMT2D* mutations almost exclusively in the youngest patients (83% <45-years-old, p=0.008). MSK-IMPACT revealed a significant increase in *FGFR3* mutations in younger patients (p<0.001).

Conclusions: Our results indicate that early-onset bladder cancer is a distinct patient population that has disease driven by specific somatic mutations, some of which represent therapeutic targets. This suggests potential benefits of genomic tumor profiling in guiding personalized treatment.

Running title: Early-onset bladder cancer

Keywords: Bladder Cancer, Early-Onset, Radical Cystectomy, Genomics, Next-Generation Sequencing

Conflict of Interest declaration: The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.

Abbreviations

FDA: Food and Drug Administration
MGB-YCC: Mass General Brigham Young Cystectomy Cohort
MSK-IMPACT: Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets
NCI: National Cancer Institute
NSQIP: National Surgical Quality Improvement Program
RC: Radical Cystectomy

Source of Funding: NCI K08CA282969-01A1 (FLC), BCAN Career Development Award (FLC), NCI 3P30CA006516-59W2 Early-Stage Surgeon-Scientist Program award (FLC).

Disclosures or conflicts: none

Word Counts:

Abstract	250		Tables	4
Introduction	514		Figures	1
Methods	586		Supplement	Yes, 2 tables 1 figure
Results	682			
Discussion	602			
Conclusion	187			
Total Main Manuscript	**2821**			

Introduction

Bladder cancer is the sixth most common malignancy in the United States, with an estimated 84,530 new cases and 17,870 deaths by 2026[1]. Despite advances in surgical management and systemic therapies, urothelial carcinoma (UC) remains a major cause of cancer-related morbidity and mortality. Environmental and lifestyle risk factors, including tobacco use and occupational carcinogen exposure to aromatic amines, account for a substantial proportion of disease burden[2-4]. Consistent with the cumulative nature of these exposures, the incidence of bladder cancer markedly increases with age. The median age at diagnosis is 73 years, and more than 90% of patients are diagnosed after age 55[1, 5]. However, early-onset bladder cancer represents a clinically important subset with unique biological and survivorship features. Previous studies have shown that younger patients are diagnosed more frequently with low-grade tumors and experience favorable long-term outcomes[6]. Nonetheless, when younger patients present with muscle-invasive or metastatic disease, tumors have a more aggressive behavior with increased rates of multifocal spread and a greater propensity for visceral metastases beyond the lymph nodes, including liver and brain involvement[7]. These results suggest that aggressive early-onset disease reflects distinct oncogenic mechanisms rather than earlier detection of urothelial carcinoma.

Younger bladder cancer patients have had less time to accumulate carcinogenic insults from smoking and environmental exposures, suggesting that tumorigenesis may rely on earlier acquisition of key driver somatic mutations or inherited germline alterations[2, 8]. Familial clustering of bladder cancer has been reported in some cases and appears independent of tobacco exposure, further supporting the contribution of germline or early life genomic events[9]. Moreover, a bladder cancer diagnosis at a young age carries disproportionate psychosocial and economic impacts, including fertility concerns, sexual dysfunction, and the need for decades of surveillance and survivorship care[10]. Progress in understanding early-onset bladder cancer has been limited in part by inconsistent definitions across studies, with widely variable age cutoffs that hinder cross-cohort comparisons and collaborative investigation[1,5]. Given the reduced cumulative exposure to traditional carcinogens, we hypothesized that early-onset bladder cancer, particularly in patients presenting with aggressive disease, may be driven by distinct molecular pathways and potentially enriched for actionable genomic alterations. Over the past decade, large-scale genomic profiling studies have substantially advanced our understanding of the biology of urothelial carcinoma across disease states. Comprehensive sequencing efforts have identified recurrent alterations in chromatin remodeling, DNA damage response, receptor tyrosine kinase signaling, and cell-cycle regulation[11-14]. These insights have led to increasingly informed therapeutic development, including biomarker-driven approaches targeting DNA repair vulnerabilities[8, 15]. Clinical trials such as ATLANTIS and BAYOU have highlighted the growing relevance of molecular stratification in advanced urothelial carcinoma[16, 17]. However, despite these advances, most genomic studies have not focused on diagnostic age, and the molecular landscape of bladder cancer in younger patients remains incompletely characterized.

Therefore, in this study, we performed comprehensive clinical and genomic profiling of young patients with aggressive early-onset bladder cancer to nominate somatic mutations and therapeutic vulnerabilities present in this subset of bladder tumors. By dissecting early-onset bladder cancer biology, we aim to advance precision oncology strategies and stimulate collaborative efforts focused on this unique population with highly unmet clinical needs.

Materials and Methods

Study Design and Patient Population

We conducted a retrospective, multi-institutional cohort study (Massachusetts General Hospital, Brigham and Women's Hospital, Memorial Sloan Kettering Cancer Institute) to characterize the clinical and genomic landscapes of early-onset bladder cancer. Early-onset disease was defined as a diagnosis before the age of 55 years, corresponding to approximately the youngest 10% of newly diagnosed bladder cancer patients based on national registry data[1, 5]. This cut-off was selected to provide a clinically meaningful and reproducible definition that enables comparisons across institutional cohorts.

Mass General Brigham Young Cystectomy Cohort

The primary institutional cohort consisted of patients treated within the Mass General Brigham system (Massachusetts General Hospital and Brigham and Women's Hospital) who underwent radical cystectomy (RC) with curative intent between 2008 and 2023. Patients were included if they had a primary diagnosis of bladder cancer and were younger than 55 years of age at the time of diagnosis. A total of 182 patients aged <55 years who underwent RC were initially identified. Exclusion criteria were applied to ensure a homogeneous cohort of bladder cancer cases treated with curative intent. Specifically, 4 patients undergoing palliative cystectomy were excluded, as were 44 patients who underwent pelvic exenteration for non–bladder cancer primary malignancies. After exclusions, the final Mass General Brigham Young Cystectomy Cohort (MGB-YCC) included 134 patients. Clinical and pathological variables were collected through structured chart review and included demographic characteristics, tumor stage and histology, perioperative treatment, and oncologic outcomes.

Institutional Tumor Sequencing

A subset of patients within the MGB-YCC cohort underwent targeted next-generation sequencing of tumor tissue as part of routine clinical care. Sequencing was performed using the institutional OncoPanel platform, a clinically validated assay designed to detect actionable somatic alterations across cancer-associated genes[18]. Genomic findings from this subset (n=17) were analyzed descriptively to assess for potential enrichment of driver mutations in early-onset aggressive disease.

External Genomic Validation Cohort

To validate the somatic genomic alterations identified in the MGB-YCC cohort, we analyzed an independent external dataset to evaluate the genomic features of early-onset bladder cancer at a larger scale. Genomic and clinical data were obtained through cBioPortal from the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) cohort[11]. This dataset includes tumor-normal matched targeted sequencing with paired blood germline samples collected between 2014 and 2021. A total of 1,313 bladder cancer patients were available. After excluding 42 patients with missing diagnostic age information, the final analytic cohort included 1,271 patients. Among these, 212 patients (16.7%) were diagnosed before the age of 55 years and met criteria for early-onset bladder cancer. Somatic alterations and pathway-level genomic features were compared between early-onset and later-onset cases.

National Surgical Quality Improvement Program

Outcomes from the MGB-YCC cohort were compared with published benchmark data from the National Surgical Quality Improvement Program (NSQIP) to contextualize the institutional results. This reference cohort included 10,848 patients undergoing radical cystectomy between 2008 and 2013, as previously reported[19]. Comparisons between MGB-YCC and NSQIP focused on perioperative and clinical outcomes in younger patients undergoing cystectomy.

Statistical Analysis

Clinical and genomic comparisons were performed using R version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables were compared using chi-square tests, while continuous variables were evaluated using Kruskal-Wallis tests. All statistical tests were two-sided, and a p-value <0.05 was considered statistically significant.

Ethical Approval

This study was conducted in accordance with institutional and ethical standards for human subject research. This project was approved by the Mass General Brigham Institutional Review Board (IRB protocol 2021P002957). Patient data were retrospectively analyzed with appropriate safeguards for confidentiality.

Results

Patient Characteristics and Clinical Features of Early-Onset Bladder Cancer

Across both institutional and external cohorts, patients with early-onset bladder cancer (diagnosis <55 years) were predominantly male and frequently presented with a clinically aggressive disease. In the Mass General Brigham Young Cystectomy Cohort (MGB-YCC; n=134), 84% of patients were male, while in the MSK-IMPACT cohort (n=212 early-onset cases), 76% were male (Tables 1–2, Tables S1–S2). The rates of muscle-invasive disease (≥T2) were comparable between cohorts, occurring in 57% of MGB-YCC patients and 54% of early-onset MSK-IMPACT patients. Smoking exposure was also common, reported in 55% and 53% of patients, respectively (Tables 1–2). Among young patients undergoing radical cystectomy in the MGB-YCC

cohort, multimodal treatment and contemporary surgical approaches were frequently used. Neoadjuvant chemotherapy was administered in 56% of cases, and urinary diversion patterns demonstrated a high utilization of continent reconstruction, with 51.5% of patients receiving continent diversion and 12% undergoing robotic-assisted procedures (Table 1, Table S1).

Clinical Comparison of Early-Onset Versus Older-Onset Disease in MSK-IMPACT

The MSK-IMPACT cohort was used to validate the MBG-YCC results. Clinical and pathological features of patients with early-onset bladder cancer patients (diagnostic age <55 years) were compared with those of patients with later-onset disease (diagnostic age ≥55) to assess age-associated differences. Early-onset patients demonstrated a similar sex distribution to that of later-onset patients (76% vs 77%, p=0.6). However, smoking prevalence was significantly lower among younger individuals (53% vs 67%, p<0.001), supporting the reduced cumulative carcinogen exposure in this population (Tables 2, S2). Younger patients also exhibited a higher proportion of low-grade tumors (10% vs 4%, p=0.001), consistent with prior studies suggesting heterogeneity in clinical behavior among early-onset cases (Tables 2, S2).

Perioperative Outcomes Compared with National Benchmarks

To contextualize outcomes in young cystectomy patients, we compared perioperative results from MGB-YCC with national benchmark data from NSQIP (n=10,848 radical cystectomy patients of all ages)[19]. The NSQIP cohort demonstrated a predominantly male population (76.4%), although smoking prevalence was substantially higher (76.6%) than that in the younger institutional cohort (Table 3). Additionally, continent diversion was far less common nationally (14.9%), consistent with older age distributions and differing practice patterns (Table 3). Thirty-day postoperative complication rates were generally comparable between cohorts. However, MGB-YCC demonstrated slightly higher rates of reported readmission (37% vs 21%), deep venous thrombosis/pulmonary embolism (DVT/PE, 9% vs 3%), and reoperation (7% vs 6%) (Table 3). These differences reflect the more granular capture of postoperative events in the institutional cohort compared with registry-based reporting rather than true excess morbidity among younger patients.

Genomic Landscape of Early-Onset Bladder Cancer

Genomic profiling of early-onset bladder cancer revealed distinct somatic alterations across cohorts (Table 4). In the institutional MGB-YCC sequencing subset, somatic mutations in *TP53* (65%) and *KMT2D* (35%) were significantly enriched in younger patients (p=0.045 and p=0.008, respectively; Table S1 and Figure S1). These findings suggest that alterations in the tumor suppressor and chromatin remodeling pathways may play a prominent role in aggressive early onset disease requiring cystectomy. Age-associated differences in recurrent driver alterations were also observed in the MSK-IMPACT cohort. Younger patients demonstrated a significant enrichment of somatic *FGFR3* mutations compared to later-onset cases (37% vs 23%, p<0.001), highlighting a potentially targetable oncogenic pathway in early-onset disease (Table 4, Figure 1). Conversely, early-onset tumors exhibited significantly lower mutation frequencies in several canonical urothelial carcinoma

drivers, including *TERT* (68% vs 75%, p=0.044), *TP53* (40% vs 50%, p=0.013), and *RB1* (12% vs 21%, p=0.007) (Table 4, Figure 1). These genomic relationships (Figure 1 and Figure S1) illustrate the enrichment of *KMT2D* somatic mutations in early-onset bladder cancer patients who underwent radical cystectomy at MGB and the increased prevalence of *FGFR3* somatic mutations in MSK-IMPACT. Collectively, these findings support the existence of distinct molecular features in early-onset bladder cancer and suggest potentially actionable pathways for further investigation.

Discussion

Early-onset bladder cancer represents a clinically important subset of urothelial carcinoma. Here we defined early-onset as a bladder cancer diagnosis before the age of 55, corresponding to the youngest 10% of patients nationally[1, 5]. This population faces unique survivorship and psychosocial challenges, including prolonged treatment burden, fertility and sexual health issues, and decades of surveillance[10]. At the same time, emerging evidence suggests that bladder cancers diagnosed in younger individuals might be biologically distinct from tumors diagnosed later in life, particularly among young patients who present with aggressive disease[2, 7, 8]. However, the clinical and molecular drivers of aggressive early-onset bladder cancer remain incompletely characterized, limiting the development of age-informed precision oncology strategies.

In this study, we provide a comprehensive clinical and genomic assessment of early-onset bladder cancer using complementary multi-institution cohorts. Our results showed that young patients with aggressive disease frequently underwent radical cystectomy with contemporary multimodal management, including high rates of neoadjuvant chemotherapy and substantial utilization of continent urinary diversion consistent with long-term quality of life goals. Importantly, overall perioperative complication rates in the MGB-YCC cohort were comparable to national NSQIP benchmarks, supporting the feasibility of aggressive surgical management in younger patients with curative intent the ultimate goal of achieving. Although postoperative events such as readmission and venous thromboembolism were reported at higher rates in the MGB-YCC cohort, this potentially reflects a more complete capture of complications through a detailed chart review compared with registry-based reporting.

Notably, early-onset patients demonstrated lower smoking prevalence compared with later-onset cases in the MSK-IMPACT cohort, consistent with reduced cumulative exposure to established carcinogenic risk factors. These results support the hypothesis that aggressive bladder cancer arising at a young age may be less driven by prolonged environmental exposure and more dependent on earlier acquisition of key oncogenic alterations or inherited susceptibility. Familial clustering independent of smoking has been described in prior studies[9], further reinforcing the need to investigate molecular pathways unique to young patients with bladder cancer.

Our study highlights the clinical heterogeneity of early-onset disease. Previous studies have shown that younger patients often present with more favorable low-grade tumors[6], but both MGB-YCC and MSK-IMPACT cohorts represent patient populations with more aggressive tumor biology; the MGB-YCC cohort was defined by patients who underwent radical cystectomy, while MSK-IMPACT reflects patients with high-risk tumors

referred to a tertiary academic center for specialized care. These observations reinforce that young patients with aggressive bladder cancer represent a subgroup of patients with an unmet need for biological discovery and therapeutic innovation.

A key contribution of this study is the identification of actionable genomic alterations enriched in early-onset bladder cancer. In the MGB-YCC cohort, we observed an increased frequency of *KMT2D* somatic mutations, implicating chromatin-remodeling pathways in aggressive early-onset disease. KMT2D encodes a histone methyltransferase with emerging relevance across tumor types, and epigenetic-targeted strategies are currently under investigation[20]. The MSK-IMPACT cohort analysis demonstrated a significant enrichment of *FGFR3* mutations in younger patients. FGFR3 mutations are clinically actionable in urothelial carcinoma through the FGFR inhibitor erdafitinib, which is already FDA-approved for metastatic disease[21]. Together, these findings suggest that early-onset bladder cancer harbors distinct genomic alterations, and that tumor sequencing in young patients could have direct therapeutic relevance because some somatic mutations present in these tumors can be therapeutically targeted.

More broadly, ongoing collaborative consensus efforts are being made to provide a clear definition of early-onset bladder cancer using reproducible national thresholds and frameworks. Because this population represents a small proportion of patients with bladder cancer, meaningful advances in biologic understanding and clinical trial development will require coordinated efforts across institutions to combine genomic data, harmonize clinical annotation, and identify recurrent targetable pathways.

Conclusions and Limitations

This study is one of the largest clinicogenomic analyses of early-onset bladder cancer and provides evidence of unique genomic alterations that can affect treatment selection. However, this study had several limitations. Both cohorts were derived from academic referral centers, which may enrich for aggressive or complex cases and limit generalizability to community-treated early-onset disease. In addition, sequencing within the institutional cohort was available only for a subset of patients, and differences in specimen type and clinical selection between cystectomy-treated and TUR-based cohorts may have influenced the observed genomic patterns.

Despite these limitations, this represents one of the largest analyses to date that integrates clinical outcomes with genomic profiling in early-onset bladder cancer. Our findings support the concept that early-onset disease, particularly in young patients with aggressive tumors, may exhibit distinct molecular features, including enrichment of actionable alterations such as FGFR3 and chromatin remodeling pathway involvement. Future multi-institutional studies with expanded sequencing and prospective clinical annotation will be essential to refine the genomic landscape of early-onset bladder cancer, validate therapeutic vulnerabilities, and ultimately enable personalized treatment strategies and dedicated clinical trials for this underserved population.

Legends

Table 1. MGB Young Cystectomy Cohort (MGB-YCC) Patient Characteristics. Demographic features, treatment history and tumor characteristics of patients in MGB-YCC cohort.

Table 2. MSK-IMPACT[a] Patient Characteristics. Demographic features, treatment history and tumor characteristics of patients in MGB-YCC cohort. Comparisons made between patients with early-onset bladder cancer (age <55 years old) and older patients (age ≥ 55) as well as subgroup analysis in early-onset patients (patients younger than 45 years old, 45-49 and 50-54 years old). Chi-square test, p-value <0.05 was considered statistically significant.

Table 3: Post-Operative Complications – MGB-YCC vs NSQIP. Comparison of complication rates after radical cystectomy in MGB-YCC and NSQIP. Fisher exact test, p-value <0.05 was considered statistically significant.

Table 4: Assessing Genomic Characteristics of Patients with Early-Onset Bladder Cancer. Comparison of characteristics and genomic mutation profiles of Mass General Brigham Young Cystectomy Cohort (MGB-YCC) and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) cohort. Early-onset bladder cancer defined as diagnosis before age 55. Additional somatic mutation characteristics provided in Table S1 and Figure S1.

Figure 1: Somatic mutation rates: Bar chart with somatic genomic mutation rates of Mass General Brigham (MGB) and Memorial Sloan Kettering (MSK) cohorts, which demonstrate a significant age-dependent distribution also available in Table 1. Notably, KMT2D and FGFR3 are enriched in MGB-YCC and MSK-IMPACT cohorts, respectively.

Table S1: Detailed MGB-YCC clinical and tumor characteristics. Detailed clinical characteristics, tumor features and mutation profiles of early-onset bladder cancer cohort (age <55 years old). Chi-square test, p-value <0.05 was considered statistically significant.

Table S2: Detailed clinical and tumor characteristics of patients in MSK-IMPACT cohort. Detailed clinical characteristics, tumor features and mutation profiles of early-onset bladder cancer cohort (age <55 years old). Chi-square test, p-value <0.05 was considered statistically significant.

Figure S1: Mutational landscape in the MGB-YCC cohort. Comutation plot represents somatic mutations profiled by MGB targeted sequencing panel (rows) in early-onset patients in the MGB-YCC cohort (columns).

References:

1. Siegel, R. L., Kratzer, T. B., Wagle, N. S. et al.: Cancer statistics, 2026. CA Cancer J Clin, **76:** e70043, 2026

2. Beatrici, E., Labban, M., Filipas, D. K. et al.: Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis. Int Braz J Urol, **50:** 199, 2024

3. Antoni, S., Ferlay, J., Soerjomataram, I. et al.: Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol, **71:** 96, 2017

4. Kiriluk, K. J., Prasad, S. M., Patel, A. R. et al.: Bladder cancer risk from occupational and environmental exposures. Urol Oncol, **30:** 199, 2012

5. Surveillance Research Program, N. C. I. A. A. f. h. s. c. g. s.-n. e. D. s. s. S. I. D., November 2023 Submission (1975-2021), SEER 22 registries. :

6. de la Calle, C. M., Washington, S. L., 3rd, Lonergan, P. E. et al.: Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database. World J Urol, **39:** 1911, 2021

7. Bianchi, M., Roghmann, F., Becker, A. et al.: Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Can Urol Assoc J, **8:** E148, 2014

8. D'Andrea, V. D., Magnani, C. J., Ernandez, J. et al.: Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. Curr Urol Rep, **26:** 12, 2024

9. Martin, C., Leiser, C. L., O'Neil, B. et al.: Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, **110:** 527, 2018

10. Dobruch, J., Daneshmand, S., Fisch, M. et al.: Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol, **69:** 300, 2016

11. Clinton, T. N., Chen, Z., Wise, H. et al.: Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep, **41:** 111859, 2022

12. Guey, L. T., Garcia-Closas, M., Murta-Nascimento, C. et al.: Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol, **57:** 283, 2010

13. Nakauma-Gonzalez, J. A., Rijnders, M., van Riet, J. et al.: Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol, **81:** 331, 2022

14. Robertson, A. G., Kim, J., Al-Ahmadie, H. et al.: Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, **171:** 540, 2017

15. Rothman, N., Garcia-Closas, M., Chatterjee, N. et al.: A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet, **42:** 978, 2010

16. Fulton, B., Jones, R., Powles, T. et al.: ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, **21:** 344, 2020

17. Rosenberg, J. E., Park, S. H., Kozlov, V. et al.: Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). J Clin Oncol, **41:** 43, 2023

18. Garcia, E. P., Minkovsky, A., Jia, Y. et al.: Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Arch Pathol Lab Med, **141:** 751, 2017

19. Reese, S. W., Ji, E., Paciotti, M. et al.: Risk factors and reasons for reoperation after radical cystectomy. Urol Oncol, **38:** 269, 2020

20. Rao, R. C., Dou, Y.: Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer, **15:** 334, 2015

21. Loriot, Y., Matsubara, N., Park, S. H. et al.: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, **389:** 1961, 2023

Table 1: MGB Young Cystectomy Cohort (MGB-YCC) Patient Characteristics

Age	Overall	< 45	45 - 49	50 - 54	p
N (%)	134 (100.0)	31 (23.1)	48 (35.8)	55 (41.0)	
Age, median [IQR][7, 8]	49 [45, 52]	41 [37, 43]	48 [46, 49]	52 [51, 53]	<0.001
Follow up - months, median [IQR]	46 [16, 89]	48 [25, 104]	25 [12, 68]	49 [26, 99]	0.04
BMI[a], mean (SD)	28.91 (5.99)	29.29 (6.48)	29.48 (6.11)	28.18 (5.61)	0.5
Male (%)	113 (84.3)	25 (80.6)	42 (87.5)	46 (83.6)	0.7
Race = White (%)	129 (96.3)	28 (90.3)	48 (100.0)	53 (96.4)	0.09
Smoking (%)	73 (54.5)	15 (48.4)	25 (52.1)	33 (60.0)	0.5
Stage ≥T2, Muscle Invasive (%)	76 (56.7)	15 (48.4)	34 (70.8)	27 (49.1)	0.048
Ileal Conduit (%)	65 (48.5)	13 (41.9)	22 (45.8)	30 (54.5)	0.5
Robotic (%)	12 (9.0)	3 (9.7)	6 (12.5)	3 (5.5)	0.5
Neoadjuvant Chemo (%)	75 (56.0)	16 (51.6)	26 (54.2)	33 (60.0)	0.7
Length of stay - days, mean (SD)	8.10 (6.04)	7.68 (4.76)	8.21 (5.78)	8.25 (6.92)	0.9
Operative time - hours, median [IQR]	8.1 [5.9, 9.6]	8.2 [6.4, 10.0]	8.4 [6.6, 9.7]	6.9 [5.5, 9.0]	0.1
Intravesical Treatment (%)					0.3
None	96 (71.6)	22 (71.0)	34 (70.8)	40 (72.7)	
BCG[b]	23 (17.2)	8 (25.8)	9 (18.8)	6 (10.9)	
Chemo	8 (6.0)	0 (0.0)	2 (4.2)	6 (10.9)	
Both	7 (5.2)	1 (3.2)	3 (6.2)	3 (5.5)	
Systemic Treatment (%)					0.8
None	49 (36.6)	13 (41.9)	17 (35.4)	19 (34.5)	
Chemo	73 (54.5)	15 (48.4)	26 (54.2)	32 (58.2)	
Immunotherapy	1 (0.7)	0 (0.0)	0 (0.0)	1 (1.8)	
Both	11 (8.2)	3 (9.7)	5 (10.4)	3 (5.5)	
Pathology, T Stage (%)					0.6
T0	27 (20.1)	8 (25.8)	6 (12.5)	13 (23.6)	
Ta	8 (6.0)	2 (6.5)	3 (6.2)	3 (5.5)	
Tis	8 (6.0)	1 (3.2)	2 (4.2)	5 (9.1)	
T1	15 (11.2)	5 (16.1)	3 (6.2)	7 (12.7)	
T2	31 (23.1)	4 (12.9)	15 (31.2)	12 (21.8)	
T3	33 (24.6)	9 (29.0)	14 (29.2)	10 (18.2)	
T4	12 (9.0)	2 (6.5)	5 (10.4)	5 (9.1)	

a = Body Mass Index (BMI). b = Bacillus Calmette-Guérin (BCG) Therapy. Additional characteristics provided in Table S1.

Table 2: MSK-IMPACT[a] Patient Characteristics

Age	Overall	< 55	≥ 55	p	< 45	45 - 49	50 - 54	p
N (%)	1271 (100.0)	212 (16.7)	1059 (83.3)		60 (28.3)	56 (26.4)	96 (45.3)	
Age, median [IQR]	66 [58, 73]	49 [43, 52]	68 [62, 75]	<0.001	38 [35, 42.5]	48 [47, 49]	53 [52, 54]	<0.001
Male (%)	980 (77.1)	160 (75.5)	820 (77.4)	0.6	45 (75.0)	48 (85.7)	67 (69.8)	0.08
Smoking (%)	813 (64.7)	111 (53.1)	702 (67.0)	<0.001	22 (36.7)	28 (51.9)	61 (64.2)	0.004
Stage ≥T2, Muscle Invasive (%)	777 (61.1)	115 (54.2)	662 (62.5)	0.03	28 (46.7)	27 (48.2)	60 (62.5)	0.09
Intravesical Treatment (%)				0.3				0.8
None	891 (70.2)	142 (67.3)	749 (70.8)		44 (73.3)	37 (66.1)	61 (64.2)	
BCG[b]	257 (20.3)	46 (21.8)	211 (19.9)		11 (18.3)	14 (25.0)	21 (22.1)	
Chemo	30 (2.4)	3 (1.4)	27 (2.6)		1 (1.7)	0 (0.0)	2 (2.1)	
Both	91 (7.2)	20 (9.5)	71 (6.7)		4 (6.7)	5 (8.9)	11 (11.6)	
Systemic Treatment (%)				0.2				NA
None	996 (78.9)	164 (78.5)	832 (79.0)		50 (83.3)	39 (72.2)	75 (78.9)	
Chemo	220 (17.4)	42 (20.1)	178 (16.9)		9 (15.0)	13 (24.1)	20 (21.1)	
Immunotherapy	16 (1.3)	0 (0.0)	16 (1.5)		0 (0.0)	0 (0.0)	0 (0.0)	
Both	30 (2.4)	3 (1.4)	27 (2.6)		1 (1.7)	2 (3.7)	0 (0.0)	
Stage (%)				0.006				0.006
Low Grade	69 (5.4)	22 (10.4)	47 (4.4)		12 (20.0)	5 (8.9)	5 (5.2)	
High Grade	378 (29.7)	65 (30.7)	313 (29.6)		17 (28.3)	24 (42.9)	24 (25.0)	
CIS[c]	47 (3.7)	10 (4.7)	37 (3.5)		3 (5.0)	0 (0.0)	7 (7.3)	
Muscle-Invasive	546 (43.0)	78 (36.8)	468 (44.2)		23 (38.3)	16 (28.6)	39 (40.6)	
Metastatic	231 (18.2)	37 (17.5)	194 (18.3)		5 (8.3)	11 (19.6)	21 (21.9)	
Histology (%)				0.3				0.4
Urothelial Carcinoma	936 (73.6)	167 (78.8)	769 (72.6)		50 (83.3)	49 (87.5)	68 (70.8)	
Squamous Cell	84 (6.6)	16 (7.5)	68 (6.4)		5 (8.3)	2 (3.6)	9 (9.4)	
Plasmacytoid	37 (2.9)	5 (2.4)	32 (3.0)		0 (0.0)	1 (1.8)	4 (4.2)	
Small Cell, Neuroendocrine	49 (3.9)	7 (3.3)	42 (4.0)		1 (1.7)	1 (1.8)	5 (5.2)	
Micropapillary	40 (3.1)	2 (0.9)	38 (3.6)		0 (0.0)	0 (0.0)	2 (2.1)	
Glandular	20 (1.6)	2 (0.9)	18 (1.7)		0 (0.0)	0 (0.0)	2 (2.1)	
Other	105 (8.3)	13 (6.1)	92 (8.7)		4 (6.7)	3 (5.4)	6 (6.2)	

a = Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) Cohort. b = Bacillus Calmette-Guérin (BCG) Therapy. c = carcinoma in situ (CIS). d = Transurethral Resection (TUR). Additional characteristics provided in Table S2.

Table 3: Post-Operative Complications – MGB-YCC vs NSQIP

	MGB Young Cystectomy Cohort (2008-2023)	NSQIP[a] (2008-2023)	p
	Age <55	**All Ages**	
N	134	10,848	
Age, mean (SD)	47.30 (5.90)	69 (10.52)	<0.001
Male (%)	113 (84.3)	8,289 (76.4)	0.04
Smoking (%)	73 (54.5)	8,310 (76.6)	0.02
Ileal Conduit (%)	65 (48.5)	9,228 (85.1)	<0.001
Complication within 30 days (%)			
Readmission (%)	50 (37.3)	2,269 (20.9)	<0.001
Ileus (%)	23 (17.2)	Not Available	
Post-operative Transfusion (%)	28 (20.9)	4,100 (37.8)	<0.001
DVT/PE[b] (%)	12 (9.0)	299 (2.8)	<0.001
Reoperation (%)	9 (6.7)	633 (5.8)	0.06

a = National Surgical Quality Improvement Program (NSQIP). b = Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE).

Table 4: Assessing Genomic Characteristics of Patients with Early-Onset[a] Bladder Cancer

	MGB-YCC[b]	MSK-IMPACT[c]			
Age	**Overall**	**Overall**	**< 55**	**≥ 55**	**p**
N (%)	**134 (100.0)**	1271 (100.0)	**212 (16.7)**	1059 (83.3)	
Age, median [IQR]	**49 [45, 52]**	66 [58, 73]	**49 [43, 52]**	68 [62, 75]	<0.001
Male (%)	**113 (84.3)**	980 (77.1)	**160 (75.5)**	820 (77.4)	0.6
Smoking (%)	**73 (54.5)**	813 (64.7)	**111 (53.1)**	702 (67.0)	<0.001
Stage ≥T2 (%)	**76 (56.7)**	777 (61.1)	**115 (54.2)**	662 (62.5)	0.03
Highlighted Mutations					
TERT	**4 (23.5)**	937 (73.7)	**144 (67.9)**	793 (74.9)	0.044
TP53	**11 (64.7)**	612 (48.2)	**85 (40.1)**	527 (49.8)	0.013
FGFR3	**1 (5.9)**	319 (25.1)	**78 (36.8)**	241 (22.8)	<0.001
KDM6A	**4 (23.5)**	332 (26.1)	**52 (24.5)**	280 (26.4)	0.6
PIK3CA	**3 (17.6)**	236 (18.6)	**46 (21.7)**	190 (17.9)	0.2
CDKN2A	**1 (5.9)**	285 (22.4)	**41 (19.3)**	244 (23.0)	0.3
ARID1A	**4 (23.5)**	299 (23.5)	**39 (18.4)**	260 (24.6)	0.06
CDKN2B	**0 (0.0)**	218 (17.2)	**36 (17.0)**	182 (17.2)	>0.9
KMT2D	**6 (35.3)**	235 (18.5)	**31 (14.6)**	204 (19.3)	0.1
CDKN1A	**2 (11.8)**	150 (11.8)	**27 (12.7)**	123 (11.6)	0.7
RB1	**4 (23.5)**	243 (19.1)	**26 (12.3)**	217 (20.5)	0.007
CCND1	**0 (0.0)**	139 (10.9)	**26 (12.3)**	113 (10.7)	0.6
ERBB2	**0 (0.0)**	192 (15.1)	**24 (11.3)**	168 (15.9)	0.1
STAG2	**1 (5.9)**	123 (9.7)	**23 (10.8)**	100 (9.4)	0.6
EP300	**0 (0.0)**	92 (7.2)	**19 (9.0)**	73 (6.9)	0.4

a = Early-onset bladder cancer defined as diagnosis before age 55, based on youngest 10% of patients with new diagnoses in national registry data. b = Mass General Brigham Young Cystectomy Cohort (MGB-YCC). c = Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) Cohort.


Cohort
MGB < 55
MSK < 55
MSK >= 55
Mutation Rate, %
100
75
50
25
0
TERT
TP53
FGFR3
KMT2D
RB1
Gene


MSK
Overall
< 45
45-49
50-54
Mutation Rate, %
100
75
50
25
0
TERT
TP53
FGFR3
KMT2D
RB1
Gene